Valuation: Shandong Weigao Group Medical Polymer Company Limited

Market Cap 12.92B 1.93B 1.7B 1.61B 1.46B 2.73B 185B 2.76B 19.28B 7.43B 94.34B 7.23B 7.07B 304B P/E 2026 *
8.55x
P/E 2027 * 7.7x
Enterprise Value 7.39B 1.1B 972M 920M 834M 1.56B 106B 1.58B 11.03B 4.25B 53.97B 4.14B 4.05B 174B EV / Sales 2026 *
0.53x
EV / Sales 2027 * 0.45x
Free-Float
51.4%
Yield 2026 *
5.23%
Yield 2027 * 5.66%
09-25 Weigao Group Medical Polymer's Affiliate Completes Acquisition of Drug Packaging Unit MT
08-25 Shandong Weigao Group Medical Polymer Company Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-25 Shandong Weigao Group Medical Polymer Company Limited Proposes Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended June 30, 2026, Payable on November 20, 2026 CI
08-24 Tranche Update on Shandong Weigao Group Medical Polymer Company Limited's Equity Buyback Plan announced on May 27, 2025. CI
08-24 Tranche Update on Shandong Weigao Group Medical Polymer Company Limited's Equity Buyback Plan announced on May 29, 2026. CI
06-08 Weigao Group's Controlling Shareholder Buys Shares MT
05-29 Shandong Weigao Group Medical Polymer Company Limited Declares Dividend for the Year Ended December 31, 2025, Payable on or Before July 10, 2026 CI
05-29 Shandong Weigao Group Medical Polymer Company Limited commences an Equity Buyback Plan for 446,464,632 shares, representing 10% of its issued share capital, under the authorization approved on May 29, 2026. CI
05-28 Shandong Weigao Group Medical Polymer Company Limited's Equity Buyback announced on May 27, 2025, has expired with 52,655,200 shares, representing 1.16% for HKD 260.91 million. CI
05-14 Shandong Weigao Group Medical Polymer says Weigao Holding purchases 3.6 million H shares RE
05-08 Weigao Group's Revenue Climbs 5% in Q1 MT
05-08 Shandong Weigao Group Medical Polymer Company Limited Reports Unaudited Revenue Results for the Three Months Ended March 31, 2026 CI
04-30 Shandong Weigao Group Medical Polymer says unit to establish fund of KRW52.965 billion RE
Manager TitleAgeSince
Chief Executive Officer 45 2021-03-29
Chief Executive Officer 52 2018-07-31
Director of Finance/CFO 48 2001-06-30
Director TitleAgeSince
Chairman 52 2021-03-29
Director/Board Member 51 2021-03-07
Director/Board Member 55 2021-03-07
Change 5-day change 1-year change 3-year change Capi.($)
-19.05%-.--% - - 1.88B
-1.06%-3.35%-25.32%+4.48% 175B
+0.24%-2.17%-8.27%+12.34% 111B
-0.82%+0.81%-25.45%+0.64% 107B
+0.69%-2.90%-47.25%-11.04% 75.31B
-1.27%-2.56%-2.63%+69.92% 58.7B
-0.96%-1.15%-3.61%-30.01% 49.57B
+1.53%+4.31%+15.99%+53.87% 49.27B
-1.20%+0.53%-17.86%+21.77% 42.02B
-0.35%-1.93%+27.86%-9.01% 32.69B
Average -2.26%-0.69%-9.62%+12.55% 77.84B
Weighted average by Cap. -0.51%-1.13%-15.71%+10.40%

Financials

2026 *2027 *
Net sales 13.82B 2.06B 1.82B 1.72B 1.56B 2.92B 198B 2.95B 20.63B 7.95B 101B 7.73B 7.57B 325B 14.55B 2.17B 1.91B 1.81B 1.64B 3.08B 208B 3.11B 21.71B 8.37B 106B 8.14B 7.96B 342B
Net income 1.5B 224M 198M 187M 170M 318M 21.49B 321M 2.24B 865M 10.98B 841M 823M 35.32B 1.66B 248M 219M 207M 187M 352M 23.76B 355M 2.48B 956M 12.13B 930M 909M 39.04B
Net Debt -5.53B -824M -727M -688M -624M -1.17B -79.05B -1.18B -8.25B -3.18B -40.37B -3.09B -3.03B -130B -6.42B -957M -844M -799M -725M -1.36B -91.82B -1.37B -9.59B -3.69B -46.89B -3.59B -3.52B -151B
Logo Shandong Weigao Group Medical Polymer Company Limited
Shandong Weigao Group Medical Polymer Co Ltd is a China-based company principally engaged in the research and development, production and sale of medical device products. The Company operates its businesses through six segments. The Medical Device Products segment produces and sells clinical care, medical testing, anesthesia and surgical related products and other consumables. The Orthopaedic Products segment produces and sells orthopaedic products, including tissue repair product line. The Interventional Products segment produces and sells tumour and blood vessel interventional instruments. The Pharma Packaging Products segment produces and sells pre-filled syringes and flushing syringes. The Blood Management Products segment produces and sells blood collection, irradiation, storage, separation and sterilization products. The Others segment engages in finance lease and factoring business. The Company mainly operates its businesses in the domestic and overseas markets.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BB